Abstract

We appreciate the opportunity to provide a response and clarifications where necessary to the points raised in the letter to editor. First, the primary goal of this analysis¹ was to contribute to the broader question of assessing the value of tumor-agnostic therapies, particularly in the context of variability in standard of care by cancer type, high uncertainty in long-term effectiveness, and limited efficacy data available at the time of trial approval. Our objective was to explore the application of various methodologies rather than to provide specific reimbursement recommendations for pembrolizumab. We observed potential heterogeneity in comparative effectiveness and value across tumor types and suggested that, wherever possible, separate comparisons should be conducted for individual tumor types.